These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 8389008)

  • 1. Neurogenic inflammation in the pathophysiology and treatment of migraine.
    Moskowitz MA
    Neurology; 1993 Jun; 43(6 Suppl 3):S16-20. PubMed ID: 8389008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The trigemino-vascular system and migraine.
    Buzzi MG; Moskowitz MA
    Pathol Biol (Paris); 1992 Apr; 40(4):313-7. PubMed ID: 1379707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model.
    Knyihár-Csillik E; Tajti J; Samsam M; Sáry G; Slezák S; Vécsei L
    J Neurosci Res; 1997 Jun; 48(5):449-64. PubMed ID: 9185668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
    Hoskin KL; Goadsby PJ
    Exp Neurol; 1998 Mar; 150(1):45-51. PubMed ID: 9514827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basic mechanisms in vascular headache.
    Moskowitz MA
    Neurol Clin; 1990 Nov; 8(4):801-15. PubMed ID: 2175382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of serotonin and other neuroactive molecules in the physiopathogenesis of migraine. Current hypotheses].
    Hamon M; Bourgoin S
    Pathol Biol (Paris); 2000 Sep; 48(7):619-29. PubMed ID: 11072640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sumatriptan in the treatment of migraine.
    Ferrari MD
    Neurology; 1993 Jun; 43(6 Suppl 3):S43-7. PubMed ID: 8389011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries.
    Hamel E; Fan E; Linville D; Ting V; Villemure JG; Chia LS
    Mol Pharmacol; 1993 Aug; 44(2):242-6. PubMed ID: 8394988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288.
    Knight YE; Edvinsson L; Goadsby PJ
    Neuropeptides; 1999 Feb; 33(1):41-6. PubMed ID: 10657470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurogenic inflammation in the context of migraine.
    Williamson DJ; Hargreaves RJ
    Microsc Res Tech; 2001 May; 53(3):167-78. PubMed ID: 11301492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model.
    Knyihár-Csillik E; Tajti J; Chadaide Z; Csillik B; Vécsei L
    Microsc Res Tech; 2001 May; 53(3):193-211. PubMed ID: 11301495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation.
    Buzzi MG; Dimitriadou V; Theoharides TC; Moskowitz MA
    Brain Res; 1992 Jun; 583(1-2):137-49. PubMed ID: 1324091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.
    Moskowitz MA
    Trends Pharmacol Sci; 1992 Aug; 13(8):307-11. PubMed ID: 1329294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma protein extravasation induced in the rat dura mater by stimulation of the parasympathetic sphenopalatine ganglion.
    Delépine L; Aubineau P
    Exp Neurol; 1997 Oct; 147(2):389-400. PubMed ID: 9344563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
    Bouchelet I; Cohen Z; Case B; Séguéla P; Hamel E
    Mol Pharmacol; 1996 Aug; 50(2):219-23. PubMed ID: 8700126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurovascular and molecular mechanisms in migraine headaches.
    Moskowitz MA; Macfarlane R
    Cerebrovasc Brain Metab Rev; 1993; 5(3):159-77. PubMed ID: 8217498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors.
    Jakubowski M; Levy D; Goor-Aryeh I; Collins B; Bajwa Z; Burstein R
    Headache; 2005; 45(7):850-61. PubMed ID: 15985101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central and peripheral mechanisms of migraine.
    Sanchez del Rio M; Reuter U; Moskowitz MA
    Funct Neurol; 2000; 15 Suppl 3():157-62. PubMed ID: 11200786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Migraine pathophysiology and its clinical implications.
    Silberstein SD
    Cephalalgia; 2004; 24 Suppl 2():2-7. PubMed ID: 15595988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization.
    Burstein R; Jakubowski M
    Ann Neurol; 2004 Jan; 55(1):27-36. PubMed ID: 14705109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.